-
PCV (Pneumococcal Conjugate)
-
Pneumococcal
Current
Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
MMWR September 12, 2024 / 73(36);793–798
-
PCV (Pneumococcal Conjugate)
-
Pneumococcal
Current
ACIP Updates: Recommendations for Use of 20-Valent Pneumococcal Conjugate Vaccine in Children ― United States, 2023
MMWR. 2023 / 72(39);1072
-
PCV (Pneumococcal Conjugate)
-
Pneumococcal
-
PPSV (Pneumococcal Polysaccharide)
Current
Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023.
MMWR. 2023 / 72(RR-3);1–39
Current
Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices—United States, 2022
MMWR, September 16, 2022, 71(37);1174–1181
Current
Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices
MMWR, January 28, 2022, 71 (4); 109-117
Current
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged 65 Years and older: Updated Recommendations of the Advisory Committee on Immunization Practices
MMWR, November 22, 2019; 68(46):1069–1075
Current
Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR, September 4, 2015; 64(34):944-947
Current
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged >65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR, September 19, 2014; 63(37):822-825
Current
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR, June 28, 2013; 62(25):521-524
Current
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR, October 12, 2012; 61(40):816-9
Archived
Licensure of 13-Valent Pneumococcal Conjugate Vaccine for Adults Aged 50 Years and Older
MMWR, June 1, 2012; 61(21):394-5
Current
Prevention of Pneumococcal Disease Among Infants and Children--Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine
MMWR, December 10, 2010; 59(RR11):1-18
Current
Updated ACIP Recommendations: Prevention of Invasive Pneumococcal Disease Among Adults Using the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23)
MMWR, September 3, 2010; 59(34):1102-6
Archived
Licensure of a 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Recommendations for Use Among Children --- Advisory Committee on Immunization Practices (ACIP), 2010
MMWR, March 12, 2010; 59(09):258-261
Archived
Updated Recommendation from the Advisory Committee on Immunization Practices (ACIP) for Use of 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Children Aged 24--59 Months Who Are Not Completely Vaccinated
MMWR, April 4, 2008; 57(13):343-344
Archived
Pneumococcal Vaccination for Cochlear Implant Candidates and Recipients
MMWR, Early Release, July 31, 2003, Vol. 52;1-2
Archived
Preventing Pneumococcal Disease Among Infants and Young Children
MMWR October 6, 2000 / Vol. 49 / No. RR-09
Archived
Prevention of Pneumococcal Disease
MMWR April 04, 1997 / Vol. 46 / No. RR-08
